Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:263 |
Name | kidney cancer |
Definition | A urinary system cancer that is located_in the kidney. |
Source | DiseaseOntology.org |
Alt Ids | DOID:3676 DOID:11834 |
Path | disease disease of cellular proliferation cancer organ system cancer urinary system cancer kidney cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PBRM1 inact mut | GSK126 | kidney cancer | predicted - sensitive | detail... |
PTEN inact mut | LY3023414 | kidney cancer | sensitive | detail... |
VHL V155fs | Sunitinib + Trametinib | kidney cancer | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00375674 | Phase III | Sunitinib | A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer (S-TRAC) | Completed | USA | SWE | SVK | POL | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | AUS | 6 |
NCT00566995 | Phase II | Vandetanib | Phase II Study of Vandetanib in Individuals With Kidney Cancer | Completed | USA | 0 |
NCT00923130 | Phase II | Bevacizumab + Ixabepilone | Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer | Completed | USA | 0 |
NCT01005797 | Phase I | Panobinostat + Sorafenib | Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers | Completed | USA | 0 |
NCT01184326 | Phase I | Everolimus + Pazopanib | An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer | Completed | USA | 0 |
NCT01217931 | Phase II | Everolimus Pazopanib Bevacizumab | Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy | Active, not recruiting | USA | 0 |
NCT01218867 | Phase Ib/II | Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin | Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes | Terminated | USA | 0 |
NCT01480154 | Phase I | Hydroxychloroquine + MK2206 | Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer | Active, not recruiting | USA | 0 |
NCT01497444 | Phase Ib/II | Evofosfamide + Sorafenib | Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT01727089 | Phase II | Bevacizumab Bevacizumab + Carotuximab | Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer | Completed | USA | AUS | 1 |
NCT02077933 | Phase I | Alpelisib + Everolimus Alpelisib + Everolimus + Exemestane | Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors | Completed | USA | NLD | ITA | HUN | GBR | FRA | ESP | DEU | 1 |
NCT02318771 | Phase I | Pembrolizumab | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02460224 | Phase Ib/II | Ieramilimab Spartalizumab | Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT02504892 | Phase II | Everolimus | Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer | Terminated | USA | 0 |
NCT02643303 | Phase Ib/II | Durvalumab + Poly ICLC Tremelimumab | A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers | Completed | USA | 0 |
NCT02899078 | Phase Ib/II | Ibrutinib + Nivolumab | Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer | Completed | USA | 0 |
NCT02964078 | Phase II | Aldesleukin + Pembrolizumab | Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer | Active, not recruiting | USA | 0 |
NCT03587662 | Phase II | Gemcitabine + Ixazomib Doxorubicin + Gemcitabine + Ixazomib | Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | Active, not recruiting | USA | 0 |
NCT03792724 | Phase Ib/II | Nivolumab + Urelumab | Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) | Unknown status | ESP | 0 |
NCT03829501 | Phase Ib/II | Atezolizumab + KY1044 KY1044 | Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer | Terminated | USA | POL | ITA | HUN | GBR | 1 |
NCT04134312 | Phase I | MVA-BN-Brachyury | A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer | Completed | USA | 0 |
NCT04148937 | Phase I | LY3475070 LY3475070 + Pembrolizumab | A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer | Completed | USA | GBR | AUS | 0 |
NCT04259450 | Phase Ib/II | AFM24 | Study to Assess AFM24 in Advanced Solid Cancers | Completed | USA | GBR | ESP | DEU | 1 |
NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT04430842 | Phase I | QBS10072S | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | Completed | AUS | 0 |
NCT04659629 | Phase I | NL-201 | NL-201 in Patients With Relapsed or Refractory Cancer | Completed | USA | CAN | AUS | 0 |
NCT05142592 | Phase I | IPG7236 | IPG7236 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05704985 | Phase I | DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | Recruiting | USA | 0 |
NCT05718557 | Phase I | PYX-106 | Study of PYX-106 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |
NCT05720117 | Phase I | PYX-201 | Study of PYX-201 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |
NCT05944237 | Phase Ib/II | Atezolizumab + HTL0039732 HTL0039732 | HTL0039732 in Participants With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT06056323 | Phase Ib/II | HB0045 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06479811 | Phase I | 212Pb-VMT-alpha-NET | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | Not yet recruiting | USA | 0 |